Effects of dexmedetomidine on blood pressure and heart rate

Comparison of the effects of dexmedetomidine and remifentanyle on blood pressure and heart rate in patients undergoing laparoscopic cholecystectomy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014010916151N1

Enrollment

Registered

2014-12-29

Start date

2013-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Heart rate. Condition 2: Blood pressure. Abnormalities of heart beat Abnormal blood-pressure reading, without diagnosis

Interventions

Intervention 1: Starting at the anesthesia, patients receive a loading dose of dexmedetomidine 1 micg/kg i.v. administerrd over 10 min followed by a continuous infusion of 0.7 micg/kg per h. Interven

Treatment - Drugs

Starting at the anesthesia, patients receive a loading dose of dexmedetomidine 1 micg/kg i.v. administerrd over 10 min followed by a continuous infusion of 0.7 micg/kg per h.

Starting at the anesthesia, patients receive a loading dose of remifentanil 1micg/kg i.v. given over 1min followed by a continuous infusion of 0.2 micg/kg/min.

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Written informed consent ;ASA physical status I and II ;20-65 years old ;BMI less than 30 kg/m2 ; Patients scheduled for elective laparoscopic cholecystectomy with general anesthesia ;Do not have respiratory disease and cardiac dysfunction and liver disease and renal disease and neuropathology and coagolopathy disease and uncontrolled hypertention ;Do not use of betablocker drugs and psycoactive drugs and analgesice drugs and opioid adiction . Exclusion criteria: uncontrolled hemodynamic chenges during surgery;open cholecystectomy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Blood pressure. Timepoint: During surgery. Method of measurement: NIBP.;Heart rate. Timepoint: During surgery. Method of measurement: ECG.	—

Secondary

Measure	Time frame
Duration of recovery room. Timepoint: Recovery room. Method of measurement: Hour.;Degree of pain. Timepoint: Recovery room. Method of measurement: VAS.;Nasa and Vomiting. Timepoint: Recovery room. Method of measurement: Observation.;Hypotention. Timepoint: During in surgery and recovery room. Method of measurement: NIBP.;Bradicardia. Timepoint: During in surgery and recovery room. Method of measurement: ECG.	—

Measure

Time frame

Duration of recovery room. Timepoint: Recovery room. Method of measurement: Hour.;Degree of pain. Timepoint: Recovery room. Method of measurement: VAS.;Nasa and Vomiting. Timepoint: Recovery room. Method of measurement: Observation.;Hypotention. Timepoint: During in surgery and recovery room. Method of measurement: NIBP.;Bradicardia. Timepoint: During in surgery and recovery room. Method of measurement: ECG.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarahnaz Sadeghi

Firouzgar Hospital

farahnazsadeghi@gmail.com+98 21 8894 6762

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026